When was PeopleBio R&D founded?

PeopleBio R&D was founded in 2002.

Where is PeopleBio R&D located?

PeopleBio R&D is headquartered in Seongnam-si, South Korea.

Where does PeopleBio R&D rank among its competitors?

PeopleBio R&D ranks 3rd amongst 56 active competitors, of which 13 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Amprion, which secured an undisclosed amount in Jul, 2026.

Who are the top competitors of PeopleBio R&D?

PeopleBio R&D's top competitors include Octave Bioscience, Amprion and Nanostics. Among them, Amprion secured the most recent funding round in July, 2026.

PeopleBio R&D - 2026 Company Profile, Funding & Competitors

Company Details

PeopleBio R&D is a molecular diagnostics company developing simple, reliable immunoassays for the detection of neurodegenerative diseases, such as Alzheimer's. The company's platform technology called the Multimer Detection System (MDS) is a sandwich ELISA test that uses a combination of capturing antibodies, and epitope-overlapping detection antibodies to differentiate between monomers and multimers of proteins. The assays are applicable to the detection of misfolded, oligomerized or aggregated proteins that are associated with diseases such as Alzheimer's, Parkinson's and Transmissible Spongiform Encephalopathies (such as Creutzfeldt-Jakob’s disease). The company has leveraged its MDS platform to develop tests to measure biomarkers of AD in the CSF, plasma, and exosomes, therapeutic antibodies for AD, and molecular diagnostic tests for Parkinson's disease from body fluids.

Website: peoplebio.net
Email ID: *****@peoplebio.net
Phone Number: +82 **********

Key Metrics

Founded Year

2002

Location

Seongnam-si, South Korea

Stage

Public

Investors

DT&Investment & 13 more

Ranked

3^rd among 56 active competitors

Similar Companies

Octave Bioscience & 70 more

Exit Details

Public

View PeopleBio R&D's full profile

PeopleBio R&D got listed on Oct 19, 2020.

Click here to take a look at PeopleBio R&D's IPO in detail

PeopleBio R&D is a funded company. PeopleBio R&D has 14 institutional investors.

View details of PeopleBio R&D's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PeopleBio R&D include Octave Bioscience, Amprion and Nanostics. Here is the list of Top 10 competitors of PeopleBio R&D, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Octave Bioscience 2014, Menlo Park (United States), Series C	Provider of AI-based molecular diagnostic tools for neurodegenrative diseases	$124M	Novartis, BVF & 14 others	65/100
2nd	Amprion 2006, Houston (United States), Series B	Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology	$11.8M	Formationve, Lilly & 3 others	56/100
3rd	PeopleBio R&D 2002, Seongnam-si (South Korea), Public	Immunoassays for early detection of neuro-degenerative diseases	-	DT&Investment, GNTech Venture Capital & 12 others	48/100
4th	Nanostics 2017, Edmonton (Canada), Seed	Developer of diagnostic tests to detect cancers, cardiovascular and neurodegenerative diseases	-	indyRIOT	40/100
5th	Cytox 2007, Oxford (United Kingdom), Series B	Developer for prognostic tests for assessing the risk of dementia	$12.1M	Maven Capital Partners, Northwest Fund & 22 others	38/100
6th	Alseres Pharmaceuticals 1972, Auburndale (United States), Public	Therapeutic and diagnostic products for disorders in the central nervous system (CNS)	$4M	Ingalls and Snyder	35/100
7th	LikeMinds 2008, Boston (United States), Series A	Provider of dopamine transporter imaging agent for diagnosis of neurodegenerative diseases	$6.37M	-	35/100
8th	Durin Life Sciences 2010, United States, Acquired	Early disease detection blood tests for Alzheimer's and Parkinson's	$5.5M	-	34/100
9th	Durin Technologies 2010, Camden (United States), Series B	Developer of the diagnostic test for neurodegenerative diseases	$8.05M	Breakthrough Diagnostics	32/100
10th	Gene Solutions 2006, Charlottesville (United States), Series A	Pioneering mitochondrial medicine, developing therapeutics for neurodegenerative and muscular diseases	$6.33M	-	32/100